地塞米松玻璃体内植入物治疗眼部疾病的研究进展

Advances in Dexamethasone Intravitreal Implant for Treatment of Ocular Diseases

随着全球人口老龄化趋势的加剧,眼部疾病的发病率显著增加,给公共卫生体系带来沉重负担。为应对这一日益严峻的视力健康挑战,开发新型治疗药物和方法已成为眼科学研究的核心课题。地塞米松玻璃体内植入物(DEX植入物)作为一种新兴的治疗手段,近年在糖尿病视网膜病变、视网膜静脉阻塞、葡萄膜炎等眼部疾病治疗中广泛应用。DEX植入物独特的药物递送系统能够在玻璃体腔内持续释放地塞米松,实现长效的抗炎和抗水肿作用。未来研究应进一步探讨DEX植入物在其他眼部疾病治疗中的潜力,并探索其与其他药物联合应用的可能性,以优化治疗效果和扩大适用范围。

With the aggravation of the aging trend of the global population,the incidence of eye diseases has increased significantly,which has brought a heavy burden to the public health system.To address the increasingly severe challenge of visual health,the development of new therapeutic drugs and methods has become a core topic in ophthalmic research.Dexamethasone intravitreal implant(DEX implant)has been widely used in the treatment of diabetic retinopathy,retinal vein obstruction,uveitis and other eye diseases as an emerging treatment option in recent years.The unique drug delivery system of DEX implant can continuously release dexamethasone within the vitreous cavity,achieving long-lasting anti-inflammatory and anti-edema effects.Future research should further explore the potential of DEX implant in the treatment of other eye diseases,and explore the possibility of their combination with other drugs to optimize the therapeutic effect and expand the application scope.